Drug treatment of multiple sclerosis | The BMJ Skip to main content Intended for healthcare
professionals Access provided by Google Indexer Subscribe My Account My email alerts BMA …

Background The influence of the patterns of onset of multiple sclerosis and relapses of the
disease on the time course of irreversible disability is controversial. Methods In 1844 …

Background Treatment with interferon beta has been shown to help patients with
established multiple sclerosis, but it is not known whether initiating treatment at the time of a …

Background: Major depression affects one in two patients with multiple sclerosis (MS) during
the course of their lifetime. This adds to the morbidity associated with the disorder and may …

When developing his disability scales for multiple sclerosis, Kurtzke demonstrated
perception and insight. However, 45 years later, the evaluation of his clinically derived …

Cognitive dysfunction is common in multiple sclerosis (MS), yet few studies have examined
effects of treatment on neuropsychological (NP) performance. To evaluate the effects of …

Objective: To evaluate the safety and efficacy of two doses of cladribine in patients with
progressive MS. Background: Treatment of progressive MS patients with cladribine in a …

A total of 754 consecutive patients with relapsing‐remitting multiple sclerosis were
investigated for interferon‐β (IFNβ) antibodies by protein‐G affinity chromatography and …

Ecological validity—the degree to which clinical tests of cognitive functioning predict
functional impairment—has recently become an area of interest in neuropsychology. The …

Brain atrophy is a relevant surrogate marker of the disease process in multiple sclerosis
(MS) because it represents the net effect of various pathological processes leading to brain …